On February 12, 2026, Amgen announced that the European Commission approved its drug UPLIZNA (inebilizumab) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for anti‑acetylcholine receptor (AChR) or anti‑muscle‑specific tyrosine kinase (MuSK) antibodies.
The approval follows the Phase III MINT study, the largest trial of its kind to include both AChR+ and MuSK+ patients. The study demonstrated durable disease control and significant steroid‑sparing benefits, with patients achieving meaningful improvements in MG‑ADL and QMG scores while tapering long‑term steroid use. UPLIZNA’s dosing schedule—two initial loading doses followed by a convenient twice‑annual maintenance dose—offers a practical advantage over many existing therapies that require more frequent administration.
In the competitive landscape, UPLIZNA stands out as the first and only CD19‑targeted therapy approved for gMG in Europe. Competitors such as argenx’s Vyvgart, UCB’s Rystiggo, and Johnson & Johnson’s Imaavy rely on FcRn blockade, whereas UPLIZNA depletes CD19‑positive B cells, directly targeting the cells that produce pathogenic autoantibodies. The twice‑annual dosing also differentiates it from FcRn inhibitors that typically require monthly or bi‑monthly infusions.
Strategically, the approval expands Amgen’s rare‑disease and immunology portfolio. UPLIZNA is already approved in Europe for IgG4‑related disease and neuromyelitis optica spectrum disorder, and the company is exploring additional autoimmune indications. The new gMG indication adds a high‑need market with limited treatment options, positioning Amgen to capture a share of a niche but growing patient population and reinforcing its manufacturing and clinical development capabilities in immunology.
Cesar Sanz Rodriguez, vice president of Medical Affairs at Amgen, said, “This approval represents an important advancement for adults with gMG in Europe, helping address debilitating symptoms and potentially reduce the long‑term use of steroids where clinically appropriate. With convenient twice‑yearly dosing and durable efficacy in people with anti‑AChR and anti‑MuSK antibody positive gMG, UPLIZNA brings a new first‑in‑class approach to managing this complex disease.”
Amgen’s Q4 2025 earnings report highlighted double‑digit revenue growth and a robust pipeline, and the company has guided 2026 revenues of $37.0–$38.4 billion. While specific sales figures for UPLIZNA in gMG are not yet disclosed, the approval is expected to contribute to the company’s overall revenue trajectory and support its broader rare‑disease strategy.
The approval is likely to strengthen Amgen’s position in the rare‑disease market, offering patients a novel therapeutic option that reduces steroid dependence and improves quality of life. By entering a market with few alternatives, Amgen can capture a meaningful share of the gMG treatment landscape and reinforce its reputation as a leader in innovative immunology therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.